Eli Lilly & Co. vs. NextCure, Inc. Common Stock
Eli Lilly & Co. (LLY) comes out ahead, leading on 4 of 6 compared factors.
Size & Scale
| LLY | NXTC | |
|---|---|---|
| Market Cap | $1.03 trillion | $33.46 million |
| Revenue (TTM) | $79.67 billion | — |
| Net Income (TTM) | $26.71 billion | $-42,748,000 |
LLY leads on 3 of 3 size & scale factors.
Valuation
| LLY | NXTC | |
|---|---|---|
| P/E Ratio | 38.70 | — |
| Price / Book | 30.33 | 2.75 |
| Price / Sales | 12.90 | — |
NXTC leads on 1 of 1 valuation factors.
Profitability
| LLY | NXTC | |
|---|---|---|
| Net Margin | 33.53% | — |
| Return on Equity | 78.84% | -351.86% |
LLY leads on 1 of 1 profitability factors.
Dividend
| LLY | NXTC | |
|---|---|---|
| Dividend Yield | 0.60% | — |
| Payout Ratio | 23.23 | — |
LLY and NXTC split the dividend factors evenly.
Risk & Sentiment
| LLY | NXTC | |
|---|---|---|
| Short Interest | 1.29% | 0.05% |
NXTC leads on 1 of 1 risk & sentiment factors.
Dig deeper: LLY overview, LLY financials, NXTC overview, NXTC financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.